EVO Valuation

Evotec SE

Add to Watchlist

Advanced Chart

3.980

+0.06(1.531%)1D

Overview
Forecast
Valuation
Earnings

EVO Relative Valuation

EVO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EVO is overvalued; if below, it's undervalued.

Historical Valuation

Evotec SE (EVO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.57 is considered Fairly compared with the five-year average of 462.62. The fair price of Evotec SE (EVO) is between 3.92 to 17.17 according to relative valuation methord.

Relative Value

Fair Zone

3.92-17.17

Current Price：3.98

Fair

-7.84

Trailing

Forward

21.39

EV/EBITDA

Evotec SE. (EVO) has a current EV/EBITDA of 21.39. The 5-year average EV/EBITDA is 36.86. The thresholds are as follows: Strongly Undervalued below -5.08, Undervalued between -5.08 and 15.89, Fairly Valued between 57.83 and 15.89, Overvalued between 57.83 and 78.79, and Strongly Overvalued above 78.79. The current Forward EV/EBITDA of 21.39 falls within the Historic Trend Line -Fairly Valued range.

-31.85

EV/EBIT

Evotec SE. (EVO) has a current EV/EBIT of -31.85. The 5-year average EV/EBIT is 52.77. The thresholds are as follows: Strongly Undervalued below -138.98, Undervalued between -138.98 and -43.11, Fairly Valued between 148.65 and -43.11, Overvalued between 148.65 and 244.53, and Strongly Overvalued above 244.53. The current Forward EV/EBIT of -31.85 falls within the Historic Trend Line -Fairly Valued range.

1.57

Evotec SE. (EVO) has a current PS of 1.57. The 5-year average PS is 4.98. The thresholds are as follows: Strongly Undervalued below -1.57, Undervalued between -1.57 and 1.71, Fairly Valued between 8.25 and 1.71, Overvalued between 8.25 and 11.52, and Strongly Overvalued above 11.52. The current Forward PS of 1.57 falls within the Undervalued range.

15.94

P/OCF

Evotec SE. (EVO) has a current P/OCF of 15.94. The 5-year average P/OCF is 37.28. The thresholds are as follows: Strongly Undervalued below -22.85, Undervalued between -22.85 and 7.21, Fairly Valued between 67.34 and 7.21, Overvalued between 67.34 and 97.40, and Strongly Overvalued above 97.40. The current Forward P/OCF of 15.94 falls within the Historic Trend Line -Fairly Valued range.

-16.17

P/FCF

Evotec SE. (EVO) has a current P/FCF of -16.17. The 5-year average P/FCF is -285.94. The thresholds are as follows: Strongly Undervalued below -2939.65, Undervalued between -2939.65 and -1612.79, Fairly Valued between 1040.92 and -1612.79, Overvalued between 1040.92 and 2367.78, and Strongly Overvalued above 2367.78. The current Forward P/FCF of -16.17 falls within the Historic Trend Line -Fairly Valued range.

Evotec SE (EVO) has a current Price-to-Book (P/B) ratio of 0.70. Compared to its 3-year average P/B ratio of 1.88 , the current P/B ratio is approximately -62.67% higher. Relative to its 5-year average P/B ratio of 3.48, the current P/B ratio is about -79.82% higher. Evotec SE (EVO) has a Forward Free Cash Flow (FCF) yield of approximately 2.61%. Compared to its 3-year average FCF yield of -7.03%, the current FCF yield is approximately -137.07% lower. Relative to its 5-year average FCF yield of -4.11% , the current FCF yield is about -163.52% lower.

0.70

P/B

Median3y

1.88

Median5y

3.48

2.61

FCF Yield

Median3y

-7.03

Median5y

-4.11

Competitors Valuation Multiple

The average P/S ratio for EVO's competitors is 0.79, providing a benchmark for relative valuation. Evotec SE Corp (EVO) exhibits a P/S ratio of 1.57, which is 100.00% above the industry average. Given its robust revenue growth of -1.01%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Maze Therapeutics Inc

Amphastar Pharmaceuticals Inc

Praxis Precision Medicines Inc

Performance Decomposition

Market capitalization of EVO increased by 1.29% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.47 to -3.80.

The secondary factor is the Revenue Growth, contributed -1.01%to the performance.

Overall, the performance of EVO in the past 1 year is driven by P/E Change. Which is more unsustainable.

-1.01%

196.00M → 194.02M

Revenue Growth

-51.29%

-52.13 → -25.39

Margin Expansion

53.59%

-2.47 → -3.80

P/E Change

1.29%